BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · BIOS.BR · EUR
Stock price, earnings
Quote as of May 26, 2026, 08:35 AM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
BioSenic S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioSenic S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioSenic S.A., a biotechnology company located in Mont-Saint-Guibert, Belgium, is dedicated to progressing clinical therapeutic solutions. The firm utilizes two primary technology platforms: an innovative allogeneic cell and gene therapy system featuring distinct bone marrow-derived mesenchymal stromal cells designed for convenient on-site hospital storage; and an Arsenic Trioxide platform. The latter is deployed in immuno-oncology to target illnesses such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's leading experimental drug, ALLOB, is currently undergoing a Phase IIb clinical trial for patients with complicated tibial fractures.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€227.60+€6.80 (+3.08%)
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
€28.90+€0.34 (+1.19%)
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
€23.40-€0.45 (-1.89%)
Fagron N.V.’s quoted price sits in the upper half of its reported 52-week range, 7.51% below the high.
€0.82-€0.01 (-0.72%)
Vivoryon Therapeutics N.V.’s quoted price sits in the lower half of its reported 52-week range, 51.07% below the high.
€0.21€0.00 (0.0%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.69% below the high.
€0.03€0.00 (0.0%)
GeNeuro S.A.’s quoted price sits in the lower half of its reported 52-week range, 79.26% below the high.
€0.00€0.00 (0.0%)
Oxurion N.V.’s quoted price sits in the lower half of its reported 52-week range, 95.89% below the high.
